APOC3 CRISPR/Cas gene therapy (Metagenomi Therapeutics/ Ionis Pharmaceuticals)

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameAPOC3 CRISPR/Cas gene therapy (Metagenomi Therapeutics/ Ionis Pharmaceuticals)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPRSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionApolipoprotein C-III inhibitors
TargetsApolipoprotein C-III
Therapy Area/IndicationsHypertriglyceridemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMetagenomi Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMetagenomi Therapeutics IncIonis Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsHypertriglyceridemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A